G. Kelly Martin
Mr. Martin is Chairman of Wren Therapeutics and has served in this position since 2018. Mr. Martin is currently Chief Executive Officer of Radius Health (Nasdaq: RDUS), a publicly quoted biopharmaceutical company committed to developing and commercializing innovative endocrine therapeutics. From 2003 to 2013, Mr. Martin was CEO of Elan Corporation plc, a pharmaceutical company focused on neurodegenerative diseases such as multiple sclerosis, Alzheimer’s, and Parkinson’s. Headquartered in Ireland, Elan operated globally and maintained several strategic partnerships including Biogen Idec and Johnson & Johnson. The company was sold to Perrigo Company plc in 2013 for more than $8.6 billion in stock and cash. Mr. Martin’s professional career started in finance having spent 22 years at Merrill Lynch & Co. Inc., leading several global divisions including Debt markets, International Equities, Systems & Technology, and the International Private Banking Group. While at Merrill Lynch, Mr. Martin lived and worked in New York, Tokyo, and London.
Chief Executive Officer
Bart Henderson is Chief Executive Officer of Wren. Bart brings extensive experience in company-building and developing innovative medicines. Previously he was operating partner at Flagship Pioneering where he led the build-out of Harbinger Health, developing an early stage cancer detection platform with leading edge artificial intelligence and machine learning technologies. Prior to Flagship, he was CEO and co-founder of Torque (now Repertoire Immune Medicines) where, under his leadership, the company significantly advanced its cellular immunotherapy pipeline, initiating the company’s first clinical trial, receiving Fast Track designation from the FDA, and building a state-of-the-art manufacturing facility for Torque’s T cell immunotherapies. Bart was founder and president of Rhythm and its subsidiary Motus which together completed successful Phase II clinical trials for two metabolic products: setmelanotide which was granted Breakthrough Designation and is the first drug approved in the US for genetic obesity; and relamorelin which was acquired by Allergan (with Motus). He was a founding employee and chief business officer of Radius, where he built the pipeline and launched the first clinical trial for Tymlos®, now approved for the treatment of osteoporosis, and acquired Elascestrant, currently in phase 3 for the treatment of metastatic breast cancer. Previously, he was an entrepreneur-in-residence at MPM Capital. He led business development at Microbia (now Ironwood Pharmaceuticals) and was head of sales and marketing at Vertex which launched its first product and significantly expanded its pipeline during his tenure. Bart previously held marketing management positions at Amgen and Merck. Bart received an M.B.A. from Dartmouth’s Tuck School of Business and a B.A. from Amherst College.
Samuel Cohen PhD
Biophysics & Kinetics
Dr. Cohen is a Founder, Board member, and former Chief Executive Officer of Wren. Dr. Cohen has a background as a research scientist, as well as experience in venture capital and strategy consulting. He was previously a Research Fellow in Biophysical Chemistry at the Centre for Misfolding Diseases at the University of Cambridge, where he worked with Wren’s other scientific founders on the chemical kinetics of protein misfolding and aggregation. Dr. Cohen's research included the development of the network kinetics theoretical framework and its application to multiple disease systems. In particular, he was part of the team that established the central role of secondary nucleation in the misfolding and aggregation pathway. Dr. Cohen was formerly an investment director at Malin plc, and a consultant in the London office of Boston Consulting Group (BCG) where he advised leading healthcare and technology companies across Europe and the US. He was also previously the Entrepreneur-in-Residence at St John’s College, University of Cambridge. Dr. Cohen graduated with bachelors and masters in Natural Sciences (Physics) and a PhD in Biophysical Chemistry from the University of Cambridge. He also spent a year as a Visiting Fellow at Harvard University. Dr. Cohen is co-author of more than 30 scientific papers. His TED talk on Alzheimer’s disease has been viewed more than 2 million times.
Prof. Michele Vendruscolo
Biophysics & Protein Regulation
Professor Vendruscolo is a Founder and Board Member of Wren. He is a Professor of Biophysics and co-director of the Cambridge Centre for Protein Misfolding Diseases at the University of Cambridge. Professor Vendruscolo's research interests are focused on the investigation of the physico-chemical principles of protein homeostasis and their application to the development of therapeutic strategies against neurodegenerative diseases. His methods offer new insights into the manner in which physics and chemistry regulate the biochemical reactions taking place in living organisms, and have led him to clarify the fundamental role that protein solubility has in the maintenance of protein homeostasis. Professor Vendruscolo has demonstrated how these approaches provide a rational basis for diagnostic and therapeutic strategies to combat some of the most prevalent and still incurable protein misfolding diseases. Professor Vendruscolo has received several awards for his work, including the Soft Matter & Biophysical Chemistry award from the Royal Society of Chemistry (2013) and the Giuseppe Occhialini Prize from the UK Institute of Physics (2017). Professor Vendruscolo received his PhD in Condensed Matter Physics in 1996 from the International School for Advanced Studies in Trieste (Italy). He then spent two years as post-doctoral fellow at the Weizmann Institute of Science (Israel), before moving to Oxford, where he worked in collaboration with Chris Dobson. He later moved to Cambridge and was appointed successively as a Royal Society University Research Fellow, a Lecturer, a Reader and a Professor (2010). Professor Vendruscolo has co-authored over 300 peer-reviewed scientific articles.
Non Executive Director
Mr. Owen Hughes is the Chief Executive Officer of Cullinan Oncology and an Executive Partner at MPM Capital. Prior to joining Cullinan and MPM, Mr. Hughes served as the Chief Business Officer and Head of Corporate Development at Intarcia Therapeutics, where he was responsible for financing, M&A, business development and operations. He led several licensing and M&A transactions, including a long term partnership with the Bill & Melinda Gates Foundation, and raised approximately $1.8 billion in private capital. Prior to Intarcia, Mr. Hughes served as a Director of Brookside Capital, a hedge fund under the Bain Capital umbrella, managing public and private healthcare investments. Prior to his tenure at Brookside, he was Senior Portfolio Manager at Pyramis Global Advisors, a Fidelity Investments Company. Owen has more than 16 years of Wall Street experience, on both the buy and sell-side. Mr. Hughes received his B.A. from Dartmouth College. Mr. Hughes currently serves on the Board of Directors of Radius Health (NASDAQ: RDUS) and Translate Bio (NASDAQ: TBIO).
Andrew von Eschenbach M.D
Non Executive Director
Dr. von Eschenbach was appointed acting Commissioner of the U.S. Food and Drug Administration in 2005, was later confirmed by the Senate as Commissioner in 2006, and then held the role until his resignation in 2009. Prior to that, Dr. von Eschenbach served as director of the National Cancer Institute at the National Institutes of Health from 2002 to 2006. Dr. von Eschenbach also previously served as a physician, surgeon, oncologist and executive, from Chairman of the Department of Urologic Oncology to Executive Vice President and Chief Academic Officer at the University of Texas M.D. Anderson Cancer Center from 1976 until 2002, and since 2009, he has continued to serve as an adjunct professor there. Dr. von Eschenbach also currently serves on the Board of Directors of Bausch Health plc, as president of Samaritan Health Initiative, senior fellow at the Bipartisan Policy Centre, and as a senior fellow at the Milken Institute. In 2006, Dr. von Eschenbach was named to the “Time 100,” the magazine’s annual list of the 100 most influential people to shape the world. Additionally, Dr. von Eschenbach was selected in both 2007 and 2008 as one of the Modern Healthcare/Modern Physician’s “50 Most Powerful Physician Executives in Healthcare.” Dr. von Eschenbach is the author of more than 300 scientific articles and studies.
Non Executive Director
Fiona has served as Company Secretary of Malin plc (ISE:MLC), a publicly listed company investing in highly innovative life sciences companies, since September 2018, prior to which she was Head of Tax from 2015. Before joining Malin, Fiona worked at Elan Corporation plc and with Deloitte’s international tax group in Dublin and New York. Fiona is an associate of the Irish Taxation Institute and of Chartered Accountants Ireland.